Feasibility Study to Evaluate Outpatient Blinatumomab in Subjects With Minimal Residual Disease (MRD) of B-precursor Acute Lymphoblastic Leukemia (ALL)
Amgen
Amgen
Pfizer
Clinigen, Inc.
Myriad Genetic Laboratories, Inc.
AstraZeneca
AbbVie
AstraZeneca
Vifor Pharma
Palleos Healthcare GmbH
Pfizer
Eli Lilly and Company
Baxter Healthcare Corporation
Novartis
Pfizer
Clinigen, Inc.
Pfizer
Qidong Gaitianli Medicines Co., Ltd
Hikma Pharmaceuticals LLC
Gilead Sciences
GlaxoSmithKline
Merck Sharp & Dohme LLC
Guerbet
China Resources Zizhu Pharmaceutical Co., Ltd.
Xian-Janssen Pharmaceutical Ltd.
Fresenius Kabi
Hoffmann-La Roche
Dong-A ST Co., Ltd.
Astellas Pharma Inc
Hoffmann-La Roche
Bayer
Boehringer Ingelheim
Merck Sharp & Dohme LLC
Orexo AB
Astellas Pharma Inc
Ortho Biotech Products, L.P.
Hoffmann-La Roche
Hoffmann-La Roche
Hoffmann-La Roche
Hoffmann-La Roche
NovoCure Ltd.
CSA Medical, Inc.
Merck Sharp & Dohme LLC
Medtronic - MITG
Advanced Medical Diagnostics s.a.
Bayer
Novartis
CSA Medical, Inc.
Hoffmann-La Roche
Janssen Pharmaceutica
AstraZeneca